BioVie (BIVI) Competitors

BioVie (NASDAQ:BIVI) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Which has more volatility & risk, BIVI or ICCC?

BioVie has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.

Is BIVI or ICCC more profitable?

ImmuCell has a net margin of 6.23% compared to BioVie's net margin of 0.00%. ImmuCell's return on equity of 6.25% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-89.02%	-75.32%
ImmuCell	6.23%	6.25%	3.87%

Do analysts prefer BIVI or ICCC?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has preferable valuation and earnings, BIVI or ICCC?

ImmuCell has higher revenue and earnings than BioVie. BioVie is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$79.10	-0.02
ImmuCell	$26.49M	2.16	-$2.16M	$0.19	33.21

Do institutionals and insiders have more ownership in BIVI or ICCC?

4.6% of BioVie shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 0.9% of BioVie shares are held by insiders. Comparatively, 5.6% of ImmuCell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media favor BIVI or ICCC?

In the previous week, ImmuCell had 4 more articles in the media than BioVie. MarketBeat recorded 5 mentions for ImmuCell and 1 mentions for BioVie. ImmuCell's average media sentiment score of 0.23 beat BioVie's score of 0.00 indicating that ImmuCell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmuCell	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ImmuCell beats BioVie on 11 of the 14 factors compared between the two stocks.